Regeneron Pharmaceuticals

This study tested an experimental drug called REGN5093-M114, alone or with another drug, in people with advanced non-small cell lung cancer (NSCLC) that makes too much MET protein. The goal was to find a safe dose and see if it could shrink tumors. The study was stopped early, an…

This study tested an experimental drug called REGN4461 in people with a rare condition called familial partial lipodystrophy, which causes abnormal fat distribution and serious metabolic issues like high triglycerides and blood sugar. The trial aimed to see if the drug could impr…

This study tested a single dose of two lab-made antibodies (casirivimab+imdevimab) given through a vein to children hospitalized with COVID-19. The goal was to see how the drug moves in the body and if it is safe. Only 2 children took part before the study was stopped early, so r…

This study tested a single dose of an experimental drug called REGN5381 in 89 people with chronic heart failure whose hearts pump less blood than normal. The goal was to check safety, side effects, and how the drug affects a key heart stress marker (NT-proBNP). The trial was term…

This study tested an experimental drug called REGN5381 for people whose high blood pressure remains uncontrolled despite taking one or more medications. The goal was to see if the drug could lower blood pressure safely. The trial was terminated early after enrolling 34 participan…

This study tested an experimental drug called REGN7257 in 17 people with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. The drug was given to patients whose disease did not get better or came back after standard immune-suppressing treat…

This early-phase study tested a new treatment called bbT369 for people with B cell non-Hodgkin's lymphoma that came back or didn't respond to standard therapy. The treatment uses a patient's own immune cells, modified to target two markers on cancer cells, plus a gene edit to imp…

This early-stage study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (PSCA). …

This study tested whether combining two drugs—vidutolimod (injected into tumors) and cemiplimab (given through a vein)—could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, lung cancer, and throat cancer. The trial enrolled 77 adults and…

This study tested a new drug combination for people with advanced melanoma that cannot be removed by surgery or has spread. The experimental treatment involved injecting CMP-001 directly into tumors along with the immunotherapy nivolumab, compared to nivolumab alone. The study wa…

This study tested a single injection of two lab-made antibodies (casirivimab and imdevimab) in children under 12 who are at high risk for severe COVID-19. The goal was to see how the antibodies behave in the body, check for side effects, and measure immune response. Only 7 childr…

This study tested a combination of two antibodies (REGN14256 and imdevimab) in adults with mild COVID-19 who were not at high risk for severe illness. The goal was to see if the treatment was safe and could reduce the amount of virus in the body. The study was stopped early, and …

This study tested whether a combination of two antibodies (casirivimab+imdevimab) could prevent symptomatic COVID-19 in people with weakened immune systems, such as transplant recipients or those on immunosuppressants. The study was terminated early after enrolling only 66 partic…